Brilinta results
September 7, 2012
REGARDLESS of smoking status,
Brilinta achieved a greater reduction
in thrombotic CV events and stent
thrombosis when compared to
clopidogrel, according to the
results from a post-hoc analysis of
patients with ACS in the PLATO trial.
The PLATO trial was a large
(18,624 patients in 43 countries),
head-to-head patient outcomes study
of Brilinta versus clopidogrel, both
given in combination with aspirin
and other standard therapy, and
patients were treated for at least 6
months and up to 12 months.
In acute coronary syndrome
patients that were medically or
invasively treated, the PLATO
analysis showed that Brilinta
significantly reduced CV deaths,
myocardial infarction and stroke for
habitual smokers (HR, 0.83 [95% CI,
0.68-1.00]) and ex/nonsmokers (HR,
0.89 [95% CI, 0.79-1.00) (interaction
P=0.50), compared to clopidogrel.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Sep 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Sep 12
